The company is now the sixth Chinese developer of a potential COVID-19 vaccine to move into human trials.
A look at the frontrunners in one of the fastest growing spaces in healthcare.
Everybody knows that biotech ideas can become huge gainers for investors, but understanding the technology platforms, the unmet needs and the valuations can be daunting, especially in spaces where
Company chart and information is provided by TradingView based on 15-minute-delayed data.
Dynavax Technologies Corp is a biopharmaceutical company. The company focuses on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor stimulation. Its current product candidates are being investigated for use in multiple cancer indications as a vaccine for the prevention of hepatitis B. Dynavax operates in the business segment of discovery, development, and commercialization of novel vaccines. Its Toll-like Receptor Immune Modulation Platform technology plays a vital role in innate immunity and subsequent adaptive immunity. The company generates the vast majority of its revenue from the sale of its HEPLISAV-B product.
| Website: | www.dynavax.com |
| Email: | narndt@dynavax.com |
| Main Phone: | +1 510 848-5100 |
| Address: | 2100 Powell Street |
| Address 2: | Suite 900 |
| State: | CA |
| City / Town: | Emeryville |
| Country: | US |
| Postal Code: | 94608 |
| Exchange: | NSC |
| CEO: | Ryan Spencer |
| Employees: | 245 |
| NAICS: | Pharmaceutical Preparation Manufacturing(325412) |
The company is now the sixth Chinese developer of a potential COVID-19 vaccine to move into human trials.
A look at the frontrunners in one of the fastest growing spaces in healthcare.
Everybody knows that biotech ideas can become huge gainers for investors, but understanding the technology platforms, the unmet needs and the valuations can be daunting, especially in spaces where
Shares of Dynavax Technologies (DVAX) are off nearly 4 percent on Thursday after a huge spike in volume just before noon. Major Trade Moves Many DVAX Shares in Short Timeframe There’s no
Clinical-stage biopharmaceutical company Dynavax Technologies Corporation (DVAX) jumped almost 6.5 percent in early trading on Friday after the company announced the pricing for its planned
Wall Street saw stocks higher by Friday’s closing bell, with all indices gaining modestly and the Standard & Poor’s 500 closing out the week on yet another record-high, and the
Giving the latest signal that the U.S. housing market is continuing to recover, the Commerce Department said this morning that construction on new homes leapt upward by 15 percent in September
The Dow Jones Industrial Average traded down to 12,748.48 in morning trading then rebounded above 12,900 in the afternoon then faded into the final half hour of trading. The NASDAQ traded down to
College degrees are exorbitant, but they don’t always have the payoff that some people expect. For those undergraduates who want to go to college but also not without the assurance that they
| Last Price N/A | Change $ N/A | Change % N/A | Tick N/A |
| Bid N/A | Bid Size N/A | Ask N/A | Ask Size N/A |
| Open N/A | High N/A | Low N/A | Prev Close N/A |
| Last Trade | Volume N/A | 52 Wk Hi N/A | 52 Wk Low N/A |
| Market Cap N/A | Ex-Div Date N/A | Div Rate N/A | Yield N/A |
| Shares N/A | EPS (TTM) N/A | PE Ratio N/A | Exchange N/A |
© 2022 Equities News | Equities.com, Inc.
* All dates and time are being displayed in Eastern Standard Time (EST).
